Partnership leverages BioHorizons' commercial network to broaden availability of Xtant's allogeneic growth factor technology, OsteoFactor Pro™, which BioHorizons will private brand as Prolifica™BELGRADE, Mont.,
Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting proceduresCompany to host investor conference call and webcast today, August
BELGRADE, Mont., Aug. 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will
BELGRADE, Mont., Aug. 4, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that Sean
Raises full-year 2026 revenue guidance to a range of $101-$105 millionSignificantly strengthens balance sheetEnters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST® Bellows product
BELGRADE, Mont., May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will
BELGRADE, Mont., May 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial
Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont. and
BELGRADE, Mont., April 9, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), in partnership with the Montana Governor's Office of Community Service (GOCS), today announced support for the Threshold of
Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-yearXtant delivers positive net income, adjusted EBITDA and operating cash flowTotal cash of $17.3 million as of December 31, 2025 with an
BELGRADE, Mont., March 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it
Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments BELGRADE, Mont., March 2, 2026 /PRNewswire/ -- Xtant Medical Holdings,
BELGRADE, Mont., Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care
nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity
BELGRADE, Mont., Dec.
Companion Spine is the first company in the world with a product portfolio solely focused on Total Disease State Solutions™ ("TDS™") for degenerative spine diseases.
This acquisition creates the
